Brasofensine
Brasofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor. It has been researched for the treatment of Parkinson’s Disease, depression and treatment of drug dependence. Phase II trials were conducted in 1996 and brasofensine was shown to be well tolerated at a dose of 4mg, but the current progress of this drug is unknown.[1][1]
See also Tesofensine
References
- ↑ Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler NR. Brasofensine treatment for Parkinson’s disease in combination with levodopa/carbidopa. Ann Pharmacother. 2002 Feb;36(2):225-30.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH